BOLERO-2: EVEROLIMUS IN COMBINATION WITH EXEMESTANE IN THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ESTROGEN RECEPTOR-POSITIVE ADVANCED BREAST CANCER REFRACTORY TO LETROZOLE OR ANASTROZOLE

被引：0

作者：

Campone, Mario ^{[1
]}

Piccart, Martine ^{[2
]}

Pritchard, Kathleen I. ^{[3
,4
]}

Xu, Cindy ^{[5
]}

Gnant, Michael ^{[6
]}

Neven, Patrick ^{[7
]}

Pistilli, Barbara ^{[8
]}

Shtivelband, Mikhail ^{[9
]}

Provencher, Louise ^{[10
]}

Masuda, Norikazu ^{[11
]}

El-Hashimy, Mona ^{[5
]}

Vittori, Luc ^{[12
]}

Sahmoud, Tarek ^{[5
]}

Baselga, Jose ^{[13
]}

Hortobagyi, Gabriel N. ^{[14
]}

机构：

[1] Ctr Reg Rene Gauducheau, St Herblain, France

[2] Inst Jules Bordet, B-1000 Brussels, Belgium

[3] Sunnybrook Odette Canc Ctr, Toronto, ON, Canada

[4] Univ Toronto, Toronto, ON, Canada

[5] Novartis Pharmaceut, Florham Pk, NJ USA

[6] Med Univ Vienna, Vienna, Austria

[7] Catholic Univ Louvain, UZ Leuven, B-3000 Louvain, Belgium

[8] Macerata Hosp, Dept Oncol, Macerata, MC, Italy

[9] Ironwood Canc & Res Ctr, Chandler, AZ USA

[10] Hop St Sacrement, Quebec City, PQ, Canada

[11] Osaka Natl Hosp, Osaka, Japan

[12] Novartis Pharma AG, Basel, Switzerland

[13] Massachusetts Gen Hosp, Boston, MA 02114 USA

[14] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

来源：

BREAST | 2011年 / 20卷

关键词：

D O I：

10.1016/j.breast.2011.08.052

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：S30 / S30

页数：1

共 50 条

[1] Everolimus in combination with exemestane in the treatment of postmenopausal women with estrogen receptor-positive metastatic breast cancer who are refractory to letrozole or anastrozole: Preliminary results of the BOLERO-2 trial
Baselga, J.
Campone, M.
Piccart-Gebhart, M. J.
Burris, H. A.
Rugo, H. S.
Noguchi, S.
Gnant, M.
Pritchard, K. I.
Lebrun, F.
Beck, J. T.
Ito, Y.
Yardley, D. A.
Deleu, I.
Perez, A.
Bachelot, T. D.
Vittori, L.
Mukhopadhyay, P.
Weber, D.
Sahmoud, T.
Hortobagyi, G. N.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[2] Everolimus in Combination with Exemestane for Postmenopausal Women with Advanced Breast Cancer Who Are Refractory to Letrozole or Anastrozole: Results of the BOLERO-2 Phase III Trial
Baselga, J.
Campone, M.
Sahmoud, T.
Piccart, M.
Burris, H.
Rugo, H.
Noguchi, S.
Gnant, M.
Mukhopadhyay, P.
Hortobagyi, G.
EUROPEAN JOURNAL OF CANCER, 2011, 47 : 6 - +
[3] The BOLERO-2 trial: the addition of everolimus to exemestane in the treatment of postmenopausal hormone receptor-positive advanced breast cancer
Beaver, Julia A.
Park, Ben H.
FUTURE ONCOLOGY, 2012, 8 (06) : 651 - 657
[4] Everolimus (EVE) for Postmenopausal Women with Advanced Breast Cancer (ABC) Refractory to Letrozole or Anastrozole: Long-term Efficacy and Safety Results of the BOLERO-2 Trial
Rugo, H.
Pritchard, K. I.
Gnant, M.
Noguchi, S.
Piccart, M.
Hortobagyi, G. N.
Burris, H. A.
Bauly, H.
Sahmoud, T.
Baselga, J.
EUROPEAN JOURNAL OF CANCER, 2012, 48 : S116 - S116
[5] Pharmacoeconomic analysis of adjuvant therapy with exemestane, anastrozole, letrozole or tamoxifen in postmenopausal women with operable and estrogen receptor-positive breast cancer
Gil J.M.
Rubio-Terrés C.
del Castillo-Saiz A.
González P.
Canorea F.
Clinical and Translational Oncology, 2006, 8 (5) : 339 - 348
[6] Everolimus plus Exemestane for Hormone Receptor-Positive Advanced Breast Cancer: A PAM50 Intrinsic Subtype Analysis of BOLERO-2
Prat, Aleix
Christoph Brase, Jan
Cheng, Yuan
Nuciforo, Paolo
Pare, Laia
Pascual, Tomas
Martinez, Debora
Galvan, Patricia
Vidal, Maria
Adamo, Barbara
Hortobagyi, Gabriel N.
Baselga, Jose
Ciruelos, Eva
ONCOLOGIST, 2019, 24 (07): : 893 - 900
[7] Everolimus Added to Exemestane Reduced Bone Markers in Postmenopausal Women with Advanced Breast Cancer (ABC): the BOLERO-2 Trial
Gnant, M.
Hortobagyi, G. N.
Rugo, H.
Burris, H. A.
Noguchi, S.
Pritchard, K. I.
Baselga, J.
Sahmoud, T.
Bauly, H.
Piccart, M.
EUROPEAN JOURNAL OF CANCER, 2012, 48 : S43 - S43
[8] Everolimus Plus Exemestane for the Treatment of Advanced Breast Cancer: A Review of Subanalyses from BOLERO-2
Hortobagyi, Gabriel N.
NEOPLASIA, 2015, 17 (03): : 279 - 288
[9] Everolimus in postmenopausal hormone-receptor-positive Advanced Breast Cancer The Breast Cancer Trials of Oral Everolimus-2 (BOLERO-2)
Hadoux, J.
Delaloge, S.
ONCOLOGIE, 2012, 14 (05) : 349 - 350
[10] BOLERO-2: Everolimus with exemestane versus exemestane alone in Asian patients with HER2-negative, hormone receptor-positive breast cancer.
Noguchi, Shinzaburo
Masuda, Norikazu
Ito, Yoshinori
Iwata, Hiroji
Mukai, Hirofumi
Horiguchi, Jun
Tokuda, Yutaka
Kuroi, Katsumasa
Iwase, Hirotaka
Inaji, Hideo
Ohsumi, Shozo
Piccart-Gebhart, Martine J.
Hortobagyi, Gabriel N.
Rugo, Hope S.
Gnant, Michael
Campone, Mario
Sahmoud, Tarek
Pritchard, Kathleen I.
Burris, Howard A.
Baselga, Jose
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)

← 1 2 3 4 5 →